This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary CCR4 Therapeutic Antibody Development
Background of CCR4
CCR4 emerges as a potential therapeutic target, especially in managing companion animal immune-mediated diseases like allergic disorders and autoimmune diseases, as well as certain cancers. BioVenic offers veterinary CCR4 therapeutic antibody development services, encompassing the entire stages from gene synthesis and animal immunization to antibody purification and characterization. By providing a comprehensive service, we are committed to assisting in developing therapeutic antibodies that block the interaction between CCR4 and its ligands, thus exploring their therapeutic potential for diseased companion animals like canines and felines.
Background of CCR4
| Full Name | C-C motif chemokine receptor 4 |
|---|---|
| Aliases | CKR4, CD194, CMKBR4, ChemR13, CC-CKR-4, K5-5. |
| Target Profile | CCR4, belonging to the G protein-coupled receptor family, is widely expressed in immune cells such as T helper cells, natural killer cells, macrophages, dendritic cells, mast cells, and eosinophils. As a crucial chemokine receptor, CCR4 binds with its chemokine ligands to exert its functions, playing a significant role in diseases such as cancer and inflammation, and maintaining immune balance. |
MoA of CCR4
CCR4 activates a cascade of reactions with its associated G proteins and intracellular signaling molecules by binding with its specific ligands, CCL17 and CCL22. This process involves various signaling pathways, including PI3K, PKC, and MAPK, affecting processes such as chemotaxis, recruitment, and adhesion of cells. The migration of immune cells like Th2 cells and Treg cells is crucial in tissue inflammatory responses and immune surveillance. In the tumor microenvironment, CCR4 binding with CCL17/CCL22 induces a concentration of Treg cells around tumor cells, exerting an immunosuppressive effect and allowing tumors to evade the immune system's threats.
Fig.1 Schematic diagram of CCR4 signaling pathways, possible functions, cellular expression, and disease connections.1
Application in Veterinary Therapeutics
The CCL17-CCR4 axis is associated with regulatory T cell infiltration in canine prostate and bladder cancer tissues, and blocking CCR4 has shown potential clinical activity and increased survival rates without severe toxic reactions. These findings suggest that targeting CCR4 could be an effective strategy to reduce Treg-mediated immune suppression and enhance the immune response against tumors. Consequently, CCR4 antibodies may play a significant role in the treatment of canine cancers. In allergic diseases, CCR4 antibodies, by blocking the CCR4 receptor highly expressed on Th2 cells, selectively inhibit the migration of Th2 cells to inflamed tissues, showing potential in treating allergic diseases such as atopic dermatitis and asthma. Studies also indicate that abnormal expression of CCR4 is associated with the progression of autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus.
Veterinary CCR4 Therapeutic Antibody Development Services
Considering the crucial role of CCR4 in canine and feline diseases, particularly allergic diseases, autoimmune disorders, and cancers, BioVenic offers veterinary CCR4 therapeutic antibody development services. We utilize various advanced antibody preparation technologies, including hybridoma cells, single B cells, and phage display techniques, to assist in developing therapeutic antibodies specifically targeting CCR4. Our services also include comprehensive antibody characterization, engineering, and species-specific antibody development to ensure the safety and efficacy of veterinary CCR4 therapeutic antibodies, enhancing the likelihood of achieving the desired therapeutic outcomes.
Please click the link below for more information about our veterinary CCR4 therapeutic antibody development services.
Why Choose Us?
BioVenic's one-stop service includes gene synthesis, animal immunization, antibody production, purification, and detailed characterization, optimized with professional support to enhance the efficiency and success rate of antibody development.
Our species-specific antibody development service meets the specific needs of different companion animals, adapting to the target species, reducing immunogenicity, and enhancing therapeutic effectiveness.
Our team employs novel technologies for high-quality veterinary therapeutic antibody development services, combined with stringent quality control processes to ensure the antibodies have high affinity and specificity.
Targeting CCR4 in a range of companion animal diseases, including asthma, atopic dermatitis, and certain cancers, is gaining wide attention. BioVenic's comprehensive service for the development of veterinary CCR4 therapeutic antibodies assists in exploring the therapeutic potential of CCR4 blockade. If you have related needs, please do not hesitate to contact us immediately.
References
- Bogacka, Joanna, et al. "CC chemokine receptor 4 (CCR4) as a possible new target for therapy." International Journal of Molecular Sciences 23.24 (2022): 15638.
- Maeda, Shingo, et al. "CCR4 blockade depletes regulatory T cells and prolongs survival in a canine model of bladder cancer." Cancer immunology research 7.7 (2019): 1175-1187.
- Maeda, Shingo, et al. "Anti-CCR4 treatment depletes regulatory T cells and leads to clinical activity in a canine model of advanced prostate cancer." Journal for Immunotherapy of Cancer 10.2 (2022).